AMD3465 is the second generation of CXCR4 antagonist that can inhibit the migration of AML cells induced by SDF‐1 and multiple intracellular signalling pathways responsible for cell survival.57 This evidence concerns the gene CXCR4 and acute myeloid leukemia.